The association between statin use and the diagnosis of prostate cancer in a population based cohort

Rodney H. Breau, Robert Jeffrey Karnes, Debra J. Jacobson, Michaela E. McGree, Steven J. Jacobsen, Ajay Nehra, Michael M. Lieber, Jennifer St. Sauver

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Purpose: The effect of statin medication use on the risk of prostate cancer is unknown. Materials and Methods: We examined data from a longitudinal, population based cohort of 2,447 men between 40 and 79 years old who were followed from 1990 to 2007. Information on statin use was self-reported and obtained by biennial questionnaires. A randomly selected subset of men (634, 26%) completed biennial urological examinations that included serum prostate specific antigen measurements. Information on prostate biopsy and prostate cancer was obtained through review of community medical records. Results: Of 634 statin users 38 (6%) were diagnosed with prostate cancer vs 186 (10%) of 1,813 nonstatin users. Statin use was associated with a decreased risk of undergoing prostate biopsy (HR 0.31; 95% CI 0.24, 0.40), receiving a prostate cancer diagnosis (HR 0.36; 95% CI 0.25, 0.53) and receiving a high grade (Gleason 7 or greater) prostate cancer diagnosis (HR 0.25; 95% CI 0.11, 0.58). Statin use was also associated with a nonsignificantly decreased risk of exceeding a prostate specific antigen threshold of 4.0 ng/ml (HR 0.63; 95% CI 0.35, 1.13). In addition, a longer duration of statin use was associated with a lower risk of these outcomes (all tests for trend p <0.05). Conclusions: Statin use is associated with a decreased risk of prostate cancer diagnosis. This association may be explained by decreased detection or cancer prevention.

Original languageEnglish (US)
Pages (from-to)494-499
Number of pages6
JournalJournal of Urology
Volume184
Issue number2
DOIs
StatePublished - 2010

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Prostatic Neoplasms
Population
Prostate-Specific Antigen
Prostate
Biopsy
Medical Records
Serum

Keywords

  • hydroxymethylglutaryl-CoA reductase inhibitors
  • population characteristics
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

The association between statin use and the diagnosis of prostate cancer in a population based cohort. / Breau, Rodney H.; Karnes, Robert Jeffrey; Jacobson, Debra J.; McGree, Michaela E.; Jacobsen, Steven J.; Nehra, Ajay; Lieber, Michael M.; St. Sauver, Jennifer.

In: Journal of Urology, Vol. 184, No. 2, 2010, p. 494-499.

Research output: Contribution to journalArticle

Breau, Rodney H. ; Karnes, Robert Jeffrey ; Jacobson, Debra J. ; McGree, Michaela E. ; Jacobsen, Steven J. ; Nehra, Ajay ; Lieber, Michael M. ; St. Sauver, Jennifer. / The association between statin use and the diagnosis of prostate cancer in a population based cohort. In: Journal of Urology. 2010 ; Vol. 184, No. 2. pp. 494-499.
@article{04141ba53ebd4193b29f52c25992d54a,
title = "The association between statin use and the diagnosis of prostate cancer in a population based cohort",
abstract = "Purpose: The effect of statin medication use on the risk of prostate cancer is unknown. Materials and Methods: We examined data from a longitudinal, population based cohort of 2,447 men between 40 and 79 years old who were followed from 1990 to 2007. Information on statin use was self-reported and obtained by biennial questionnaires. A randomly selected subset of men (634, 26{\%}) completed biennial urological examinations that included serum prostate specific antigen measurements. Information on prostate biopsy and prostate cancer was obtained through review of community medical records. Results: Of 634 statin users 38 (6{\%}) were diagnosed with prostate cancer vs 186 (10{\%}) of 1,813 nonstatin users. Statin use was associated with a decreased risk of undergoing prostate biopsy (HR 0.31; 95{\%} CI 0.24, 0.40), receiving a prostate cancer diagnosis (HR 0.36; 95{\%} CI 0.25, 0.53) and receiving a high grade (Gleason 7 or greater) prostate cancer diagnosis (HR 0.25; 95{\%} CI 0.11, 0.58). Statin use was also associated with a nonsignificantly decreased risk of exceeding a prostate specific antigen threshold of 4.0 ng/ml (HR 0.63; 95{\%} CI 0.35, 1.13). In addition, a longer duration of statin use was associated with a lower risk of these outcomes (all tests for trend p <0.05). Conclusions: Statin use is associated with a decreased risk of prostate cancer diagnosis. This association may be explained by decreased detection or cancer prevention.",
keywords = "hydroxymethylglutaryl-CoA reductase inhibitors, population characteristics, prostatic neoplasms",
author = "Breau, {Rodney H.} and Karnes, {Robert Jeffrey} and Jacobson, {Debra J.} and McGree, {Michaela E.} and Jacobsen, {Steven J.} and Ajay Nehra and Lieber, {Michael M.} and {St. Sauver}, Jennifer",
year = "2010",
doi = "10.1016/j.juro.2010.03.149",
language = "English (US)",
volume = "184",
pages = "494--499",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - The association between statin use and the diagnosis of prostate cancer in a population based cohort

AU - Breau, Rodney H.

AU - Karnes, Robert Jeffrey

AU - Jacobson, Debra J.

AU - McGree, Michaela E.

AU - Jacobsen, Steven J.

AU - Nehra, Ajay

AU - Lieber, Michael M.

AU - St. Sauver, Jennifer

PY - 2010

Y1 - 2010

N2 - Purpose: The effect of statin medication use on the risk of prostate cancer is unknown. Materials and Methods: We examined data from a longitudinal, population based cohort of 2,447 men between 40 and 79 years old who were followed from 1990 to 2007. Information on statin use was self-reported and obtained by biennial questionnaires. A randomly selected subset of men (634, 26%) completed biennial urological examinations that included serum prostate specific antigen measurements. Information on prostate biopsy and prostate cancer was obtained through review of community medical records. Results: Of 634 statin users 38 (6%) were diagnosed with prostate cancer vs 186 (10%) of 1,813 nonstatin users. Statin use was associated with a decreased risk of undergoing prostate biopsy (HR 0.31; 95% CI 0.24, 0.40), receiving a prostate cancer diagnosis (HR 0.36; 95% CI 0.25, 0.53) and receiving a high grade (Gleason 7 or greater) prostate cancer diagnosis (HR 0.25; 95% CI 0.11, 0.58). Statin use was also associated with a nonsignificantly decreased risk of exceeding a prostate specific antigen threshold of 4.0 ng/ml (HR 0.63; 95% CI 0.35, 1.13). In addition, a longer duration of statin use was associated with a lower risk of these outcomes (all tests for trend p <0.05). Conclusions: Statin use is associated with a decreased risk of prostate cancer diagnosis. This association may be explained by decreased detection or cancer prevention.

AB - Purpose: The effect of statin medication use on the risk of prostate cancer is unknown. Materials and Methods: We examined data from a longitudinal, population based cohort of 2,447 men between 40 and 79 years old who were followed from 1990 to 2007. Information on statin use was self-reported and obtained by biennial questionnaires. A randomly selected subset of men (634, 26%) completed biennial urological examinations that included serum prostate specific antigen measurements. Information on prostate biopsy and prostate cancer was obtained through review of community medical records. Results: Of 634 statin users 38 (6%) were diagnosed with prostate cancer vs 186 (10%) of 1,813 nonstatin users. Statin use was associated with a decreased risk of undergoing prostate biopsy (HR 0.31; 95% CI 0.24, 0.40), receiving a prostate cancer diagnosis (HR 0.36; 95% CI 0.25, 0.53) and receiving a high grade (Gleason 7 or greater) prostate cancer diagnosis (HR 0.25; 95% CI 0.11, 0.58). Statin use was also associated with a nonsignificantly decreased risk of exceeding a prostate specific antigen threshold of 4.0 ng/ml (HR 0.63; 95% CI 0.35, 1.13). In addition, a longer duration of statin use was associated with a lower risk of these outcomes (all tests for trend p <0.05). Conclusions: Statin use is associated with a decreased risk of prostate cancer diagnosis. This association may be explained by decreased detection or cancer prevention.

KW - hydroxymethylglutaryl-CoA reductase inhibitors

KW - population characteristics

KW - prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=77955467109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955467109&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2010.03.149

DO - 10.1016/j.juro.2010.03.149

M3 - Article

C2 - 20620405

AN - SCOPUS:77955467109

VL - 184

SP - 494

EP - 499

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -